gabexate
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02710266)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Kallikrein 1INHIBITOR
Kallikrein 1 inhibitor
- ThrombinINHIBITOR
F2 inhibitor
- PlasminINHIBITOR
Plasmin inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)c1ccc(OC(=O)CCCCCNC(=N)N)cc1- Mol. weight
- 321.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL87563 ↗
Also known as
- gabexate
- gabexate
- gabexate
- gabexate
- gabexate
- gabexate
- gabexate
- gabexate mesilate
- gabexate mesilate
- gabexate mesilate
- gabexate mesilate
- gabexate mesylate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02710266 | Phase 3 | Feb 1, 2016 | Yonsei University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2016 |
1 organizations
Page 1 / 1